FY2025 Performance and FY2026 Projections
Takeda has announced its financial results for the fiscal year 2025, ending on 31st March 2026. The company reported a 1.7% decrease in revenue year-on-year. Despite this, Takeda is optimistic about FY2026, with plans for significant product launches.
The Osaka-based pharmaceutical giant's revenue decline was mainly due to losing exclusivity for its drug VYVANSE. Growth and Launch Products helped offset this loss to some extent. Core revenue saw a 2.6% decrease at constant exchange rates.
Takeda reported an increase in core operating profit by 0.8% at actual exchange rates, despite a 0.9% decline at constant exchange rates. Operational expenditure savings enabled this growth while continuing investments for future expansion.
Reported operating profit increased significantly by 19.3% year-on-year at actual exchange rates. This increase reflected reduced amortization expenses for VYVANSE and lower restructuring costs.
Core EPS rose by 5.2% at actual exchange rates and by 3.1% at constant exchange rates. Meanwhile, reported EPS surged by 78.1% year-on-year, showcasing strong financial management.
Pipeline and Future Developments
Takeda completed regulatory submissions for oveporexton and rusfertide, with U.S. commercial launches expected in the second half of 2026. Zasocitinib is set for a planned regulatory filing in 2026 and commercial launch in the first half of 2027.
Takeda Chief Executive Officer-elect, Julie Kim, expressed confidence, saying, "FY2025 was a pivotal year, validating the strength of our execution against demanding development and regulatory milestones." The focus remains on growth transformation and transitioning to new blockbuster brands.
For FY2026, Takeda forecasts a low single-digit decline in core revenue alongside a mid-teens decline in core EPS. Despite this, the company plans to maintain strong cash flow to support long-term growth and shareholder returns.
Takeda's Chief Financial Officer, Milano Furuta, emphasised disciplined cost control and growth investment, stating, "In FY2025, despite topline headwinds, we delivered solid profit and cash flow through disciplined cost control, while directing growth investment toward new product launches and the pipeline."
Takeda will provide further insights into its FY2025 financial performance during an investor call on 13th May 2026. The webcast will be available on their investor relations website for those interested in detailed information.
